Physician profile
Ellen D Doyle
NPI 1174774061
$3,217.01
in general payments reported to CMS, 2019-2025
11 companies · $1,638 in 2025
The $1,638 reported for 2025 was more than what 89% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $461 · 2022: $239 · 2023: $381 · 2024: $497 · 2025: $1,638.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,437 · Education: $79.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,436.64 |
| Education | $79.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,073.34 | 2021-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $624.43 | 2022-2025 | Uzedy, Austedo Xr, Austedo |
| Alkermes, INC. | $388.06 | 2021-2024 | Vivitrol |
| Abbvie INC. | $343.69 | 2024-2025 | |
| Braeburn INC. | $267.21 | 2024-2025 | Brixadi |
| Neurocrine Biosciences, INC. | $170.12 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $150.70 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| E.R. Squibb & Sons, L.L.C. | $135.45 | 2025 | Cobenfy |
| Janssen Pharmaceuticals, INC | $25.06 | 2023 | Invega Sustenna |
| Indivior INC. | $20.50 | 2021 | |
| Redhill Biopharma INC. | $18.45 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ellen Doyle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.